slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,129
Current window 31,171-31,200
Pages 2,605
Rows per page 30
Component
31,171-31,200 of 78,129
03
The chart uses a 1-7 Likert scale to compare mean responses across three survey questions.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
04
The chart is a diverging bar chart showing 'No' vs 'Yes' responses, with a calculated 'Difference' column.2018 Manufacturing Priorities Survey · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
03
The chart uses a dual-line plot to show the divergence between healthcare and general inflation, with a shaded region for the Great Recession.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
04
Data shows hospital-related services as the primary driver of recent healthcare inflation.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
05
The chart uses a grouped bar structure to compare annual inflation trends across 12 specific healthcare sub-segments.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Mece Breakdown1 hit
08
The chart highlights a divergence between healthcare inflation and general inflation, with a specific forecast range for healthcare.Perspectives on US Healthcare Inflation Insights from L.E.K. Consulting · L.E.K. Consulting
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
12
The slide combines quantitative survey data (N=101) with qualitative expert quotes to contextualize the market sentiment.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
16
The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
17
The chart displays 4 categories of FDA designations with stacked segments representing product types.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
18
The slide highlights the 'me-too' drug development problem in China.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
20
The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
24
The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
26
The chart highlights factors directly related to commercial attractiveness in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
27
The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
32
The chart combines a horizontal bar chart for penetration rates with a stakeholder usage matrix.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
34
The slide uses a combination of quantitative survey data and qualitative expert quotes to validate the trend towards smart clinical trial formats.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
40
Survey data from IQVIA/L.E.K. Consulting (N=56).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
43
The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
46
The slide uses a stacked bar chart to represent survey data (N=81) and includes two testimonial quotes from R&D leads.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
50
The slide presents qualitative interview profiles and quantitative survey respondent demographics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
03
The chart is a waterfall representation of survey responses regarding future IT outsourcing spend.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
04
The chart uses a stacked bar format to illustrate market growth across three segments: ITO, BPO, and Application development.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
05
The chart shows a bridge from 100 to 92, with a +5 increase and a -13 decrease.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
06
The slide highlights a shift in spending towards specialized IT services.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
07
The slide uses a 100% stacked bar chart to show the shift in revenue mix and its impact on operating profit.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
05
The chart uses bubble size to represent the number of global surgical procedures and position on the curve to represent penetration level.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
06
The slide uses a bar chart to visualize market growth and a callout box to highlight the projected market value.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
11
The chart uses a broken axis for the U.S. data point to accommodate the large difference in scale.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next Steps1 hit
12
The chart uses a grid-based timeline to represent months, with color-coded bars indicating current approval times and potential reduction intervals.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next Steps1 hit